bevacizumab,panitumumab
amgen,roche,takeda
['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'paradigm']
dr. yoshino lba1 #asco22: paradigm evaluates mfolox6 + bev vs mfolfox6 + panit in pts w/ left sided crc 
Oncologist & Chief Medical Science Officer @ASCO #CancerLinQ. Classical/choral music fan ???? https://t.co/GxpBhxmsFj. RT or like may mean I agree; or not. Tweets=only moi